Quinten Health will be at the Real-World Evidence and Market Access Conference in Frankfurt, Germany.
Alexandre Templier (President)will attend as a speaker the Real-World Evidence and Market Access Conference – EU Edition.
In this session, he will unveil next-generation disease and care models, powered by artificial intelligence, to support drug clinical development, market access and life cycle.
These cutting-edge innovations empower pharmaceutical laboratories to accelerate and de-risk late stage clinical trials, market approvals, pricing negotiations, and phase 4 designs optimization.
Live Session hosted by Alexandre Templier on “Accelerate and de-risk Clinical Development & Market Access through AI-powered Real- World Disease and Care simulation.”
Alexandre Templier, our President, will speak on October 5th from 11:50am to 12:20pm.
“Accelerate and de-risk Clinical Development & Market Access through AI-powered Real-World Disease and Care simulation.”
Based on a solid track record of success stories in regulatory and HTA contexts; Alexandre will describe concrete and proven ways to extrapolate evidence from clinical trials to predict Real-World long-term effects and medico-economic impact, and forecast the value of drugs in development.
Artificial intelligence and machine learning approaches hold the key to delivering reliable projections, bridging the gap between trials and real-world scenarii. Simulated cohorts offer exciting possibilities: simulating future compounds, emulating trials, and projecting long-term outcomes before market launch and even before Phase 3 trials.
About Real-World Evidence and Market Access Conference – EU Edition
After five successful editions of Real-World Evidence and Life Sciences Analytics Conference in Boston, USA, MarketsandMarkets is proud to announce its upcoming Europe edition of Real-World Evidence and Market Access Conference to be held on October 5th- 6th 2023 at The Westin Grand Frankfurt, Germany. The conference will bring the full spectrum of experts, leaders, and stakeholders to share a board prospective on significant points and hold discussions on the best practices, with a key takeaway being better decision making.
WHAT TO EXPECT
- Regulatory view around data quality & data standards.
- Leveraging RWE for improving market access.
- The adoption & role of AI & ML in clinical trials.
- Real-world evidence & Digital Health – The expanded role of RWE for digital health.
- Real-World Data & Advanced Analytics.
- RWE to inform decision making process in rare diseases where there is lack of evidence.